Abituzumab in SSc-ILD
Stopped Difficulties experienced in identifying participants who meet the eligibility criteria of the trial.
Conditions
- Systemic Sclerosis-associated Interstitial Lung Disease
Interventions
- DRUG: Abituzumab 1500 mg
- DRUG: Abituzumab 500 mg
- DRUG: Placebo
Sponsor
EMD Serono Research & Development Institute, Inc.
Collaborators